Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level?

Copyright: dolgachov / 123RF Stock Photo

This comes arsenic Nuvation Bio Inc (NYSE:NUVB) works to grow the marketplace for its lung crab drug. On June 29, Nuvation Bio said that the UK cause regulator had accepted the selling exertion for its lung crab cause and would reappraisal the petition to determine whether to o.k. oregon cull it. The selling exertion was submitted by Nuvation Bio's spouse Eisai.

The drug, known arsenic taletrectinib, targets precocious ROS1-positive non-small compartment lung cancer. Nuvation Bio has already secured selling approvals for the cause successful the US, Japan, and China. It is seeking the drug's support successful the UK and different planetary markets.

In the meantime, Nuvation Bio is shoring up its equilibrium sheet. The institution exited Q1 2026 with $533.7 cardinal successful ash, currency equivalents, and marketable securities and precocious raised $287.5 cardinal done a notes offering.

Nuvation Bio Inc (NYSE:NUVB) is simply a planetary biopharmaceutical institution focused connected processing targeted therapies for cancers. The institution aims to code unmet needs successful crab treatment. Its pipeline includes cause candidates targeting lung crab and gliomas.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Seth Klarman Stock Portfolio: 10 Best Stocks to Top 10 Mid Cap Stocks to Own for Decades According to Hedge Funds.

Disclosure: None. Follow Insider Monkey connected Google News.